calcium polystyrene sulfonate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4871 37286-92-3

Description:

MoleculeDescription

Synonyms:

  • calcium polystyrene sulfonate
  • calcium polystyrene sulphonate
  • calcium polystyrenesulfonate
  • kalimate
  • Molecular weight:
  • Formula: (C16H14CaO6S2)n
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
45 g O

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal impairment 63.64 36.49 30 911 75631 50528552
Hyperkalaemia 49.60 36.49 22 919 48067 50556116
Cardiac failure 40.02 36.49 22 919 76018 50528165

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Crystal deposit intestine 72.27 29.30 11 1656 90 29572770
Hyperkalaemia 71.84 29.30 44 1623 61348 29511512
Renal impairment 41.01 29.30 35 1632 81298 29491562

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperkalaemia 111.47 28.56 64 2785 101065 64394818
Renal impairment 92.06 28.56 63 2786 134954 64360929
Crystal deposit intestine 74.08 28.56 12 2837 197 64495686
Cardiac failure 52.95 28.56 45 2804 132328 64363555
Hepatic function abnormal 46.07 28.56 31 2818 64282 64431601
Shunt stenosis 43.64 28.56 10 2839 1057 64494826
Anaemia 37.65 28.56 63 2786 378617 64117266
Interstitial lung disease 36.55 28.56 32 2817 97700 64398183
Chronic kidney disease 34.64 28.56 25 2824 57894 64437989

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC V03AE01 VARIOUS
ALL OTHER THERAPEUTIC PRODUCTS
ALL OTHER THERAPEUTIC PRODUCTS
Drugs for treatment of hyperkalemia and hyperphosphatemia
MeSH PA D002411 Cation Exchange Resins
MeSH PA D002614 Chelating Agents
MeSH PA D007475 Ion Exchange Resins
MeSH PA D064449 Sequestering Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperkalemia indication 14140009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
HUI2S00793 UNII
D03270 KEGG_DRUG
C0108139 UMLSCUI
CHEBI:53277 CHEBI
CHEMBL2109033 ChEMBL_ID
169893 PUBCHEM_CID
C003321 MESH_SUPPLEMENTAL_RECORD_UI
28210-41-5 SECONDARY_CAS_RN
75905 PUBCHEM_CID
DB01344 DRUGBANK_ID
1546437 RXNORM
003509 NDDF
006664 NDDF
1002242008 SNOMEDCT_US
395788004 SNOMEDCT_US
710808009 SNOMEDCT_US
C0137904 UMLSCUI
CHEMBL1201484 ChEMBL_ID
8324 INN_ID
ZSL2FB6GXN UNII

Pharmaceutical products:

None